Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung CancerMassimo Di Maïo, Cesare Gridelli, Fortunato Ciardiello et al.|Journal of Thoracic Oncology|2012Cited by 26
Epidermal Growth Factor Receptor (Egfr) and Abcg2 Polymorphisms and Treatment Outcome in the Randomized Phase III Torch Trial in Advanced Non-Small Cell Lung Cancer (Nsclc) PatientsGeoffrey Liu, Francesco Perrone, Massimo Di Maïo et al.|Annals of Oncology|2014Cited by 0